References
- Guideline on Similar Biological Medical Products. Committee for Medicinal Products for Human Use; European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf. Accessed December 12, 2014.
- Guidelines on Evaluaion of Similar Biotheraprutic Products. Expert Committee on biological standardization; World Health Organization. Available from: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed December 12, 2014.
- Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry. US Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Available from: http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/Guidances/UCM291128.pdf. Accessed March 12, 2014.
- Guidance for Industry: Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product. US Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER); Center for Biologics Evaluation and Research (CBER). Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM397017.pdf. Accessed March 12, 2014.
- Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision). Committee for Medicinal Products for Human Use; European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/04/WC500089474.pdf. Accessed December 9, 2014.
- Guidance for Industry. Listed Drugs, 30-Month Stays, and Approval of ANDAs and 505(b)(2) Applications Under Hatch-Waxman, as Amended by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Questions and Answers. U.S. Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research. Available from http://www.fda.gov/OHRMS/DOCKETS/98fr/2004n-0087-gdl0001.pdf. Accessed December 9, 2014.
- Mann J, Mahinka SP. Biosimilars: patent challenges and competitive effects. LMG Life Sci. 2014;(1):33–36.
- Blank T, Netzer T, Hildebrandt W, Vogt-Eisele A, Kaszkin-Bettag M. Safety and toxicity of biosimilars – EU versus US regulation. GABI. 2013; 2(3):144–150.
- Wizemann V, Rutkowski B, Baldamus C, Scigalla P, Koytchev R; Epoetin Zeta Study Group. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment. Curr Med Res Opin. 2008;24(3):625–637.
- Krivoshiev S, Wizemann V, Czekalsk S, et al. Therapeutic equivalence of epoetin zeta and alfa, administered subcutaneously, for maintenance treatment of renal anemia. Adv Ther. 2010;27(2):105–117.
- Tamilvanan S, Raja NL, Sa B, Basu SK. Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following heir parenteral administration into human body. J Drug Target. 2010;18(17):489–498.
- Walsh G. Post-Translational Modifications in the Context of Therapeutic Proteins: An Introductory Overview. Post-translational Modification of Protein Biopharmaceuticals. West Sussex, UK: Wiley-Blackwell. 2009;1–14.
- Locatelli F, Del Vecchio L. Erythropoiesis-stimulating agents in renal medicine. Oncologist. 2011;16(Suppl 3):19–24.
- Lonnemann G, Wrenger E. Biosimilar epoetin zeta in nephrology: effect of injection frequency on weekly dose. Int J Clin Med. 2012;3: 598–602.
- Scientific discussion. European Medicines Agency. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000872/WC500054374.pdf. Accessed November 26, 2014.
- Kirkov V, Dimitrova V, Siebert-Weigel M, et al. Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 1st communication: a monocentric, open, randomized, single dose, two-period crossover trial in healthy volunteers. Arzneimittelforschung. 2008;58:215–219.
- Kirkov V, Dimitrova V, Siebert-Weigel M, et al. Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 2nd communication: a monocentric, double-blind, randomized, single dose, three period crossover trial in healthy volunteers. Arzneimittelforschung. 2008;58:220–224.
- Krivoshiev S, Todorov V, Manitius J, Scigalla P, Koytchev R, Epoetin Zeta Study Group. Comparison of the therapeutic effects of epoetin zeta and epoetin alfa in the correction of renal anaemia. Curr Med Res Opin. 2008;24:1407–1415.
- Mikhail A, Farouk M. Epoetin biosimilars in Europe: five years on. Adv Ther. 2013 ;30(1):28–40. Epub December 12, 2012.
- Sabbatini M, Vitale S, Garofalo G, et al. Efficacy of subcutaneous epoetin-zeta on anemia in renal transplant recipients: a single-center experience. Transplant Proc. 2014;46(7):2238–2240.
- Michallet M, Luporsi E, Soubeyran P, et al. Biosimilars in the management of anaemia secondary to chemotherapy in haematology and oncology: results of the ORHEO observational study. BMC Cancer. 2014;14:503. Erratum in BMC Cancer. 2014;14:720.
- Dammacco F, Castoldi G, Rödjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. Br J Haematol. 2001;113(1):172–179. Erratum in Br J Haematol. Sep 2001;114(3):738.
- Drüeke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355(20):2071–2084.
- Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355(20):2085–2098.
- Baldamus C, Krivoshiev S, Wolf-Pflugmann M, Siebert-Wiegel M, Koytchev R, Bronn A. Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther. 2008;25:1215–1228.
- Wieçek A, Ahmed I, Scigalla P, Koytchev R. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: post hoc analysis. Adv Ther. 2010;27:941–952.
- Dellanna F, Fluck R, Lonnemann G, et al. Results from a safety study of patients with renal anemia receiving the biosimilar Retacrit™/Silapo™ (epoetin zeta): the PASCO I study. Poster 64. National Kidney Foundation 2014 Spring Clinical Meetings; 22–26 April, 2014; Las Vegas, USA.
- Ebbers HC, Chamberlain P. Interchangeability: an insurmountable fifth hurdle? GaBI Journal. 2014;3(2):88–93.
- Davis-Ajami ML, Wu J, Downton K, Ludeman E, Noxon V. Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility. Biologics. 2014;8:155–167.
- Bajraktar J, Lazarova B, Najdovska E, Mihajlova L. DSL-011 efficacy and safety of epoetin zeta in dialysis patients. Eur J Hosp Pharm Sci Pract. 2013;20:A91.
- Perani L, Scolari C, Braus A, Galli E. Switch from CERA to EPO zeta in patients with anaemia and chronic kidney disease. Eur J Hos Pharm Sci Pract. 2013;20:A64.
- Macdougall IC. Biosimilar epoetins. Nephrol Dial Transplant. 2009;24(5):1698–1699; author reply 1699–1700.
- Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002 ;40(3):439–446.
- Rossert J, Casadevall N, Eckardt KU. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol. 2004;15(2):398–406.
- Pure Red Cell Aplasia: Patient information. RareRenal.org; Information on rare kidney diseases. Available from: http://rarerenal.org/patient-information/pure-red-cell-aplasia-patient-infromation/. Accessed December 11, 2014.
- Bennett CL, Jacob S, Hymes J, Usvyat LA, Maddux FW. Anaphylaxis and hypotension after administration of peginesatide. N Engl J Med. May 22, 2014;370(21):2055–2056.
- Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355(10):1018–1028.
- Piga M, Chessa E, Ibba V, et al. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort. Autoimmun Rev. 2014;13(8):873879.
References
- Fishbane S, Schiller B, Locatelli F, et al. Peginesatide in patients with anemia undergoing hemodialysis. N Engl J Med. 2013;368(4):307–319.
- Macdougall IC, Provenzano R, Sharma A, et al. Peginesatide for anemia in patients with chronic kidney disease not receiving dialysis. N Engl J Med. 2013;368(4):320–332.
- Mikhail A. Profile of peginesatide and its potential for the treatment of anemia in adults with chronic kidney disease who are on dialysis. J Blood Med. 2012;3:25–31. doi: 10.2147/JBM.S23270. Epub May 23, 2012.
- Food and Drug Administration. Revised Package Insert for Omontys (Peginesatide). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202799s001lbl.pdf. Accessed December, 4 2012.
- Bennett CL, Jacob S, Hymes J, Usvyat LA, Maddux FW. Anaphylaxis and hypotension after administration of peginesatide. N Engl J Med. May 22, 2014;370(21):2055–2056.